Warde Medical Laboratory

Background: Telepsychiatry has the potential to be a viable substitute for in-person consultations, as the frequency of mental health issues in children and adolescents rises. This highlights the need for accessible psychiatric treatment. Objective: The purpose of this research was to compare the efficacy of conventional in-person psychiatric therapy with telepsychiatry in terms of treatment adherence, patient satisfaction, and clinical improvement in pediatric populations. Methodology: A prospective cohort research with 518 individuals aged 5 to 18 years who had been diagnosed with mental problems was carried out from January to December 2023 at Bacha Khan Medical College, Mardan. Either the in-person care group (n=195) or the telepsychiatry group (n=323) received the participants' assignments. The Children's Global Assessment Scale (CGAS) and Clinical Global Impressions (CGI) scores were used to quantify clinical improvement, and structured questionnaires and session attendance records were used to examine patient satisfaction and treatment adherence. Baseline characteristics were summed up using descriptive statistics, and independent t-tests were used to compare clinical outcomes between the two groups for continuous variables. P-values less than 0.05 were regarded as statistically significant. Results: Both groups exhibited significant clinical improvements over 12 months. The telepsychiatry group (n=323) demonstrated an increase in CGAS scores from a baseline of 45.25 (SD ±10.37) to 78.62 (SD ±5.37) (p=0.048), while the in-person care group (n=195) improved from 44.81 (SD ±10.54) to 80.35 (SD ±4.96) (p=0.048). For patient satisfaction, the telepsychiatry group reported a mean score of 8.29 (SD ±1.58), compared to 8.53 (SD ±1.37) in the in-person group (p=0.211). Treatment adherence rates were 80.86% in the telepsychiatry group (1,310 of 1,620 sessions attended) and 84.52% in the in-person group (989 of 1,170 sessions attended). Overall, 186 participants (57.58%) in the telepsychiatry group reported significant clinical improvement compared to 119 participants (61.02%) in the in-person care group (p=0.134). Conclusion: Telepsychiatry is an effective alternative to traditional care for children and adolescents, yielding comparable clinical outcomes and patient satisfaction while improving access to mental health services. Keywords: telepsychiatry, pediatric psychiatry, mental health, clinical outcomes, patient satisfaction, treatment adherence.

This report presents the proceedings from a workshop titled “Microbiome, Metabolism and Immunoregulation of Asthma” that was held virtually May 13 and 14, 2021. The workshop was jointly sponsored by the American Thoracic Society (Assembly on Allergy, Immunology, and Inflammation) and the National Institute of Allergy and Infectious Diseases. It convened an interdisciplinary group of experts with backgrounds in asthma immunology, microbiome science, metabolomics, computational biology, and translational pulmonary research. The main purpose was to identify key scientific gaps and needs to further advance research on microbial and metabolic mechanisms that may contribute to variable immune responses and disease heterogeneity in asthma. Discussions were structured around several topics, including 1) immune and microbial mechanisms of asthma pathogenesis in murine models, 2) the role of microbes in pediatric asthma exacerbations, 3) dysregulated metabolic pathways in asthma associated with obesity, 4) metabolism effects on macrophage function in adipose tissue and the lungs, 5) computational approaches to dissect microbiome–metabolite links, and 6) potential confounders of microbiome–disease associations in human studies. This report summarizes the major points of discussion, which included identification of specific knowledge gaps, challenges, and suggested directions for future research. These include questions surrounding mechanisms by which microbiota and metabolites shape host health versus an allergic or asthmatic state; direct and indirect influences of other biological factors, exposures, and comorbidities on these interactions; and ongoing technical and analytical gaps for clinical translation.

The diagnostic workup of lymphoma continues to evolve rapidly as experience and discovery led to the addition of new clinicopathologic entities and techniques to differentiate them. The optimal clinically effective, efficient, and cost-effective approach to diagnosis that is safe for patients can be elusive, in both community-based and academic practice. Studies suggest that there is variation in practice in both settings. To develop an evidence-based guideline for the preanalytic phase of testing, focusing on specimen requirements for the diagnostic evaluation of lymphoma. The American Society for Clinical Pathology, the College of American Pathologists, and the American Society of Hematology convened a panel of experts in the laboratory workup of lymphoma to develop evidence-based recommendations. The panel conducted a systematic review of literature to address key questions. Using the Grading of Recommendations Assessment, Development, and Evaluation approach, recommendations were derived based on the available evidence, strength of that evidence, and key judgements as defined in the Grading of Recommendations Assessment, Development, and Evaluation Evidence to Decision framework. Thirteen guideline statements were established to optimize specimen selection, ancillary diagnostic testing, and appropriate follow-up for safe and accurate diagnosis of indolent and aggressive lymphoma. Primary diagnosis and classification of lymphoma can be achieved with a variety of specimens. Application of the recommendations can guide decisions on specimen suitability, diagnostic capabilities, and correct use of ancillary testing. Disease prevalence in patient populations, availability of ancillary testing, and diagnostic goals should be incorporated into algorithms tailored to each practice environment.

Phase III studies of bevacizumab in advanced pancreas cancer (APCA) demonstrated no improvement in outcome. No validated biomarkers for bevacizumab efficacy exist. We evaluated bevacizumab-related hypertension (B-HTN) as a biomarker in APCA patients in a pooled analysis from 4 prospective clinical trials of gemcitabine-based therapy combined with bevacizumab. Data were collected from individual databases from 4 prospective, single-arm phase II trials. Patients were grouped according to B-HTN or no hypertension (HTN), and patients with HTN were further grouped according to highest Common Terminology Criteria for Adverse Events grade of HTN: grade 1-2 or grade 3-4. Clinical outcomes of overall survival, time to progression, overall response rate (ORR), and disease control rate (ORR+SD>16 wk) were compared. A total of 163 patients with stage IV APCA and Eastern Cooperative Oncology Group 0-1 were included. Median age was 59 years (range, 33 to 85 y). Thirty-four patients had B-HTN, and 129 patients had no HTN. Prognostic factors were balanced between groups. Patients with any grade B-HTN had a significantly improved median overall survival (13.1 vs. 8.1 mo, P=0.0006), median time to tumor progression (7.6 vs. 5.5 mo, P=0.0074), ORR (47% vs. 16%, P=0.0001), and disease control rate (85% vs. 59%, P=0.004). There were no differences in outcomes according to HTN grade (1-2 [N=16] vs. 3-4 [N=18]). APCA patients who develop any grade of B-HTN appear to derive benefit from bevacizumab. Additional investigation is needed to identify subgroups of patients who develop B-HTN and are more likely to benefit from bevacizumab.

Monoclonal gammopathies (M proteins) are associated with an extraordinarily broad array of clinical conditions that range from monoclonal gammopathy of undetermined significance (MGUS)1 to multiple myeloma. Three basic goals of the methods used to investigate M proteins are detection, immunochemical characterization, and quantification. Serum protein electrophoresis (SPE) techniques have undergone considerable improvements in the past few decades and now provide crisp resolution (especially in the β region) to detect many subtle electrophoretic differences in M proteins not readily distinguished by older 5-band gel techniques. Immunofixation (IFE) has replaced immunoelectrophoresis to become the gold standard for detecting an M protein and characterizing its isotype. Despite these advances, however, problems in detecting and especially in quantifying M proteins persist. By SPE, M proteins can migrate anywhere from the α to the γ region. They can be obscured by large proteins, such as haptoglobin in the α2 region or more commonly by transferrin and complement component 3 (C3) in the β region (1). Occasionally, IgM M proteins self-aggregate, creating problems with detection and measurement. Although most cases of multiple myeloma feature relatively large M protein peaks that are readily detected, even with low-resolution 5-band methods, 15%–20% of patients with multiple myeloma produce only free immunoglobulin light chains that, because of their relatively small molecular weights, are rapidly cleared into the urine, often producing no detectable M protein spike after SPE. Indeed, many cases of monoclonal free light chains (Bence Jones protein) cannot be identified by IFE of serum; however, IFE of concentrated early morning void (or 24-h urine) remains a reliable means to detect such small molecular weight M proteins. Unfortunately, urine samples too often are not submitted along with serum samples for the initial evaluation. With the development by Bradwell et al. in 2001 of highly specific assays for free …

Capillary electrophoresis (CE) is capable of distinguishing hemoglobin E (HbE) from hemoglobin A(2) (HbA(2)), thus permitting quantification of HbA(2) in patients with HbE. In this study, routine samples submitted for evaluation of hemoglobinopathy that demonstrated HbE were studied by high-pressure liquid chromatography and CE. The data for 52 samples from adult HbE heterozygotes were compared with those for a control group consisting of 209 patients. The mean HbA(2) of patients with HbE trait was 3.4% (SD, 0.4%), which was significantly higher (P < .001) than the 2.6% (SD, 0.4%) for the control group. Seven samples from adults homozygous for HbE were also evaluated. The mean HbA(2) of HbE homozygotes was 4.4%, which was significantly greater (P < .001) than the HbA(2) values for the HbE heterozygotes. Data from these cases provide an estimate of the range of HbA(2) in patients with HbE when evaluated by CE.